title: Cardiovascular risk factors in chronic treatment with antipsychotic agents used in primary care.
abstract: OBJECTIVE
  To compare the prevalence of cardiovascular risk factors (CVRF) and vascular events, between patients treated and untreated with antipsychotic drugs.
  
  
  METHODS
  A cross-sectional study was done in Barcelona. We compared patients attended in Primary Health Care Centres, treated with or without antipsychotics between 2008 and 2010. Anthropometric measurements, clinical variables, and CVRF were assessed. Adult and elderly patients, typical and atypical antipsychotics, were studied separately.
  
  
  RESULTS
  14,087 patients had been prescribed antipsychotics (63.4% atypical), the most common being risperidone. We selected 13,724 patients with the same age and gender but not treated (total of 27,811 patients). Patients receiving antipsychotic had higher prevalence of obesity (16.9% vs. 11.9%), smoking (22.2% vs. 11.1%), diabetes mellitus (16% vs. 11.9%), and dyslipidemia (32.8% vs. 25.8%) (p < 0.001). The prevalence of stroke was significantly higher in the treated patients, both in adults (odds ratio = 2.33) and the elderly (odds ratio = 1.64). The prevalence of coronary heart disease was similar in both groups (odds ratio = 0.97). Among patients treated with antipsychotic, differences were not observed depending typical or atypical ones.
  
  
  CONCLUSIONS
  Patients treated with antipsychotic drugs had a greater prevalence of several CVRF (diabetes mellitus, obesity, and smoking). The presence of stroke was higher in those treated with antipsychotics. No relevant differences were observed between patients receiving typical or atypical antipsychotics.
authors.affiliation: Institut Catala de la Salut, Barcelona, Espana.
authors.forename: Xavier
authors.initials: X
authors.lastname: Mundet-Tudurí
authors.forename: Manuel
authors.initials: M
authors.lastname: Iglesias-Rodal
authors.forename: Carmen
authors.initials: C
authors.lastname: Olmos-Domínguez
authors.forename: M Lluïsa
authors.initials: ML
authors.lastname: Bernard-Antoranz
authors.forename: M Isabel
authors.initials: MI
authors.lastname: Fernández-San Martín
authors.forename: Ester
authors.initials: E
authors.lastname: Amado-Guirado
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000886:Anthropometry; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D002908:Chronic Disease; D015897:Comorbidity; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D003920:Diabetes Mellitus / Q000453:epidemiology; D004363:Drug Utilization; D050171:Dyslipidemias / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy / Q000453:epidemiology; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents